Abstract
About 500 million people all over the world are chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV) and are thus at high risk of developing liver fibrosis, cirrhosis or hepatocellular carcinoma. While in adults about 90% of acutely HBV-infected patients clear the virus, only 30% of acute HCV infections clear spontaneously. Several mechanisms contribute to the failure in viral clearance. The main factors responsible for the chronification of HBV and HCV infection are, on the one hand, viral escape mutations leading to lack of recognition by antiviral immune cells and, on the other hand, loss of antiviral effector functions of virus-specific CD8+ T cells, called T-cell exhaustion. This review focuses on the latter highlighting current knowledge about the heterogeneity of exhausted CD8+ T cells and the potential for re-invigoration of exhausted T-cell populations during chronic viral hepatitis. Although direct-acting antivirals successfully clear chronic HCV infection, there is still the need for a prophylactic vaccine to prevent primary infection. Moreover, a therapeutic strategy eliminating HBV infection still does not exist. A better understanding of T-cell exhaustion and the potential for functional recovery will help to develop new immunotherapeutic approaches for chronic viral hepatitis.
References
1.
Schweitzer A, et al: Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546-1555.
2.
Messina JP, et al: Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61:77-87.
3.
Cooper S, et al: Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-449.
4.
Lechner F, et al: Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
5.
Rehermann B, et al: The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995;181:1047-1058.
6.
Thimme R, et al: Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002;99:15661-15668.
7.
Shoukry NH, et al: Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645-1655.
8.
Thimme R, et al: CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
9.
Nitschke K, et al: CD8+ T-cell responses in hepatitis B and C: the (HLA-) A, B, and C of Hepatitis B and C. Dig Dis 2016;34:396-409.
10.
Rehermann B, et al: Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest 1995;96:1527-1534.
11.
Desmond CP, et al: Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease. J Virol 2012;86:1181-1192.
12.
Kefalakes H, et al: Adaptation of the hepatitis B virus core protein to CD8(+) T-cell selection pressure. Hepatology 2015;62:47-56.
13.
Neumann-Haefelin C, et al: Virological and immunological determinants of intrahepatic virus-specific CD8+ T-Cell failure in chronic hepatitis C virus infection. Hepatology 2008;47:1824-1836.
14.
Cox AL, et al: Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005;201:1741-1752.
15.
Boni C, et al: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215-4225.
16.
Gruener NH, et al: Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001;75:5550-5558.
17.
Lechner F, et al: Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
18.
Gallimore A, et al: Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998;187:1383-1393.
19.
Zajac AJ, et al: Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998;188:2205-2213.
20.
Angelosanto JM, et al: Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J Virol 2012;86:8161-8170.
21.
Wherry EJ: T cell exhaustion. Nat Immunol 2011;12:492-499.
22.
Bengsch B, et al: Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010;6:e1000947.
23.
Schurich A, et al: Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011;53:1494-1503.
24.
Owusu Sekyere S, et al: A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. J Hepatol 2015;62:31-40.
25.
Wherry EJ, et al: Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007;27:670-684.
26.
Blackburn SD, et al: Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10:29-37.
27.
Buggert M, et al: T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog 2014;10:e1004251.
28.
Knolle PA, Thimme R: Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 2014;146:1193-1207.
29.
Battegay M, et al: Enhanced establishment of a virus carrier state in adult Cd4+ T-cell-deficient mice. J Virol 1994;68:4700-4704.
30.
Ng CT, Oldstone MB: IL-10: achieving balance during persistent viral infection. Curr Top Microbiol Immunol 2014;380:129-144.
31.
Boettler T, et al: T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005;79:7860-7867.
32.
Cabrera R, et al: An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004;40:1062-1071.
33.
Stoop JN, et al: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005;41:771-778.
34.
Speiser DE, et al: T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol 2014;14:768-774.
35.
Liang TJ, et al: Present and future therapies of hepatitis B: from discovery to cure. Hepatology 2015;62:1893-1908.
36.
Baumert TF, et al: A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J Hepatol 2014;61(1 suppl):S34-S44.
37.
Moskophidis D, et al: Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-761.
38.
Zhou X, et al: Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future. Viruses 2012;4:2650-2669.
39.
Blackburn SD, et al: Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A 2008;105:15016-15021.
40.
Paley MA, et al: Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012;338:1220-1225.
41.
Zhou X, et al: Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. Immunity 2010;33:229-240.
42.
Utzschneider DT, et al: T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity 2016;45:415-427.
43.
Im SJ, et al: Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 2016;537:417-421.
44.
He R, et al: Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection. Nature 2016;537:412-428.
45.
Pauken KE, Wherry EJ: Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015;36:265-276.
46.
Barber DL, et al: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-687.
47.
Brahmer JR, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
48.
Webster DP, Klenerman P, Dusheiko GM: Hepatitis C. Lancet 2015;385:1124-1135.
49.
Fisicaro P, et al: Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010;138:682-693, 693.e1-e4.
50.
Liu J, et al: Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014;10:e1003856.
51.
Pauken KE, et al: Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 2016;354:1160-1165.
52.
Callendret B, et al: T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. Hepatology 2014;60:1531-1540.
53.
Martin B, et al: Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 2014;61:538-543.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
